Carrick Acquires Rights to CT900, Plans New Trial in Ovarian Cancer Patients

Carrick Acquires Rights to CT900, Plans New Trial in Ovarian Cancer Patients
Carrick Therapeutics, a biopharmaceutical company, has acquired the rights to CT900 and plans to conduct a later-stage clinical trial to evaluate the safety and effectiveness of the investigational therapy in women with resistant or refractory ovarian cancer. The Institute of Cancer Research (ICR) and global health company BTG, the original developers of the therapy candidate,

Knowledge is power when living with ovarian cancer.

Get access to the web’s leading Ovarian Cancer news & insights for as little as 16¢/day.
Subscribe or to access all post and page content.

Leave a Comment

Your email address will not be published. Required fields are marked *